drugset / Trial / NCT00657202

Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1

NCT00657202

Phase 0 Completed 11 enrolled Massachusetts General Hospital
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to determine if ranibizumab can prevent the growth of neurofibromas. We will also be collecting extra blood and serum samples to help us learn more about NF1. Ranibizumab is a drug that affects the development of blood vessels that feed tumors. It targets a substance in the body called VEGF (Vascular Endothelial Growth Factor). VEGF helps tumors to grow and survive by supporting the growth of blood vessels that bring nutrients to the tumor. VEGF is made by cancerous tumors and also by non-cancerous tumors such as neurofibromas.

Timeline

Start
2008-03
Primary completion
2009-10
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ranibizumab Monoclonal antibody Other